-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
SGLT2 inhibitors are a new class of antihyperglycemic drugs mechanism, which reduces type II diabetes patients with poor cardiac vascular risk and renal events
Diabetes, heart blood vessels metformin Recently researchers compared the effects of SGLT2 inhibitors and sulfonylureas in patients with type II diabetes, all-cause mortality
This study used data from the US veterans database to investigate the use of SGLT2 inhibitors and sulfonylureas in patients with type II diabetes on the basis of metformin treatment
The average age of the participants was 64.
Compared with sulfonylurea drugs, the use of SGLT2 inhibitors is associated with a reduction in all-cause mortality of patients (hazard ratio [HR]=0.
Studies believe that compared with sulfonylureas, the use of metformin-SGLT-2 inhibitor combination therapy can reduce the risk of all-cause death in patients with type II diabetes
Compared with sulfonylureas, combined treatment with metformin-SGLT-2 inhibitors can reduce the risk of all-cause death in patients with type II diabetes.
Original source:
Yan Xie et al.
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabete.
JAMA
Leave a message here